Hostname: page-component-669899f699-rg895 Total loading time: 0 Render date: 2025-04-24T12:41:30.097Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study

Published online by Cambridge University Press:  14 October 2024

Sarah E. Moore Open the ORCID record for Sarah E. Moore [Opens in a new window] ,
Matthew Song Open the ORCID record for Matthew Song [Opens in a new window] ,
Elena A. Swingler Open the ORCID record for Elena A. Swingler [Opens in a new window] ,
Stephen Furmanek ,
Thomas Chandler Open the ORCID record for Thomas Chandler [Opens in a new window] ,
Dakota Smith ,
Martin T. Brenneman Open the ORCID record for Martin T. Brenneman [Opens in a new window]  and
Ashley M. Wilde Open the ORCID record for Ashley M. Wilde [Opens in a new window]
Sarah E. Moore*
Affiliation:
Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA
Matthew Song
Affiliation:
Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA
Elena A. Swingler
Affiliation:
Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA
Stephen Furmanek
Affiliation:
Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA
Thomas Chandler
Affiliation:
Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA
Dakota Smith
Affiliation:
Norton Healthcare, Department of Pharmacy, Louisville, KY, USA
Martin T. Brenneman
Affiliation:
Baptist Health Hardin, Department of Pharmacy, Elizabethtown, KY, USA
Ashley M. Wilde
Affiliation:
Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY, USA
*
Corresponding author: Sarah E. Moore; Email: sarah.moore@nortonhealthcare.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To compare rates of Clostridioides difficile infection (CDI) recurrence following initial occurrence treated with tapered enteral vancomycin compared to standard vancomycin.

Design:

Retrospective cohort study.

Setting:

Community health system.

Patients:

Adults ≥18 years of age hospitalized with positive C. difficile polymerase chain reaction or toxin enzyme immunoassay who were prescribed either standard 10–14 days of enteral vancomycin four times daily or a 12-week tapered vancomycin regimen.

Methods:

Retrospective propensity score pair matched cohort study. Groups were matched based on age < or ≥ 65 years and receipt of non-C. difficile antibiotics during hospitalization or within 6 months post-discharge. Recurrence rates were analyzed via logistic regression conditioned on matched pairs and reported as conditional odds ratios. The primary outcome was recurrence rates compared between standard vancomycin versus tapered vancomycin for treatment of initial CDI.

Results:

The CDI recurrence rate at 6 months was 5.3% (4/75) in the taper cohort versus 28% (21/75) in the standard vancomycin cohort. The median time to CDI recurrence was 115 days versus 20 days in the taper and standard vancomycin cohorts, respectively. When adjusted for matching, patients in the taper arm were less likely to experience CDI recurrence at 6 months when compared to standard vancomycin (cOR = 0.19, 95% CI 0.07–0.56, p < 0.002).

Conclusions:

Larger prospective trials are needed to elucidate the clinical utility of tapered oral vancomycin as a treatment option to achieve sustained clinical cure in first occurrences of CDI.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 45 , Issue 12 , December 2024 , pp. 1435 - 1441
Check for updates
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Data previously presented as a poster at IDWeek 2023 in Boston, Massachusetts, U.S.A.

References

CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.Google Scholar
Lurienne, L, Bandinelli, PA, Galvain, T, Coursel, CA, Oneto, C, Feuerstadt, P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes 2020;4:14.CrossRefGoogle ScholarPubMed
Johnson, S, Lavergne, V, Skinner, AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis 2021;73:e1029–e1044.CrossRefGoogle Scholar
Kelly, CR, Fischer, M, Allegretti, JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol 2021;116:1124–1147.CrossRefGoogle ScholarPubMed
McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–e48. doi: 10.1093/cid/cix1085 CrossRefGoogle Scholar
van Prehn, J, Reigadas, E, Vogelzang, EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021;27 Suppl 2:S1–S21. doi: 10.1016/j.cmi.2021.09.038 CrossRefGoogle ScholarPubMed
McFarland, LV, Surawicz, CM, Rubin, M et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:44–50.CrossRefGoogle ScholarPubMed
Fekety, R, McFarland, LV, Surawicz, CM et al. Recurrent Clostridium difficile diarrhea: characteristics and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324–33.CrossRefGoogle Scholar
Polivkova, S, Krutova, M, Capek, V, Sykorova, B, Benes, J. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection: an observational cohort study. Int J Infect Dis 2021;103:226–233. doi: 10.1016/j.ijid.2020.11.004 CrossRefGoogle ScholarPubMed
McFarland, LV, Elmer, GW, Surawicz, CM. Breaking the Cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769–1775.CrossRefGoogle ScholarPubMed
Abou Chakra, CN, Pepin, J, Sirard, S, Valiquette, L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014;9:e98400.CrossRefGoogle ScholarPubMed
Vardakas, KZ, Polyzos, KA, Patouni, K, Rafailidis, PI, Samonis, G, Falagas, ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012;40:1–8.CrossRefGoogle ScholarPubMed
Nelson, WW, Scott, TA, Boules, M et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm 2021;27:828–838.Google ScholarPubMed
Deshpande, A, Pasupuleti, V, Thota, P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015;36:452–60.CrossRefGoogle ScholarPubMed
Majors, D, Ellis, P. Risk factors for recurrent Clostridium difficile infections and strategies to decrease readmissions in a community hospital. Hosp Pharm 2015;50:1003–1010.CrossRefGoogle Scholar
Hensgens, M, Goorhuis, A, Dekkers, O, Kuijper, E. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012;67:742–748.CrossRefGoogle ScholarPubMed
Guery, B, Menichetti, F, Anttila, V et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label phase 3b/4 trial. Lancet Infect Dis 2018;18:296–307.CrossRefGoogle ScholarPubMed
Wilcox, MH, Gerding, DN, Poxton, IR et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017;376:305–317.CrossRefGoogle ScholarPubMed
Louie, TJ, Miller, MA, Mullane, KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422–431.CrossRefGoogle ScholarPubMed
Cornely, OA, Crook, DW, Esposito, R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281–289.CrossRefGoogle Scholar
Sirbu, BD, Soriano, MM, Manzo, C, Lum, J, Gerding, DN, Johnson, S. Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection. Clin Infect Dis 2017;65:1396–1399.CrossRefGoogle ScholarPubMed
Kassam, Z, Cribb Fabersunne, C, Smith, MB, et al. Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther 2016;43:725–733. doi: 10.1111/apt.13546 CrossRefGoogle Scholar
Brown, KA, Khanafer, N, Daneman, N, Fisman, DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013;57:2326–2332.CrossRefGoogle ScholarPubMed
Brown, K, Valenta, K, Fisman, D, Simor, A, Daneman, N. Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med 2015;175:626–633.CrossRefGoogle ScholarPubMed
Brown, KA, Langford, B, Schwartz, KL, Diong, C, Garber, G, Daneman, N. Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis 2021;72:836–844.CrossRefGoogle ScholarPubMed
Webb, BJ, Subramanian, A, Lopansri, B, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection. Antimicrob Agents Chemother 2020;64:e02169–19.CrossRefGoogle ScholarPubMed
Chesnaye, NC, Stel, VS, Tripepi, G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J 2021;15:14–20. doi: 10.1093/ckj/sfab158. PMID: 35035932; PMCID: PMC8757413.CrossRefGoogle ScholarPubMed
Rubin, DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001;2:169–188.CrossRefGoogle Scholar
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2023. https://www.R-project.org/ Google Scholar
Mikamo, H, Tateda, K, Yanagihara, K et al. Efficacy and safety of fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. J Infect Chemother 2018;24:744–752.CrossRefGoogle Scholar
U.S. National Library of Medicine. Initial vancomycin taper for prevention of recurrent Clostridium difficile infection (TAPER-V). Available at: History of Changes for Study: NCT04138706 (clinicaltrials.gov). Accessed July 26, 2022.Google Scholar
Olsen, MA, Yan, Y, Reske, KA, Zilberberg, MD, Dubberke, ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect 2015;21:164–170. doi: 10.1016/j.cmi.2014.08.017 CrossRefGoogle ScholarPubMed
Feuerstadt, P, Nelson, WW, Drozd, EM, et al. Mortality, health care use, and costs of Clostridioides difficile infections in older adults. J Am Med Dir Assoc 2022;23:1721–1728.e19. doi: 10.1016/j.jamda.2022.01.075 CrossRefGoogle ScholarPubMed
Alsoubani, M, Chow, JK, Rodday, AM, Kent, D, Snydman, DR. The comparative effectiveness of fidaxomicin compared to vancomycin in populations with immunocompromising conditions for the treatment of Clostridioides difficile infection, a single center study. Open Forum Infect Dis 2023;11:ofad622. https://doi.org/10.1093/ofid/ofad622 Google ScholarPubMed
Mithani, Z, Cooper, J, Boyd, JW. Race, power and COVID-19: a call for advocacy within bioethics. Am J Bioethics 2020;21:11–18.CrossRefGoogle Scholar
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter Suppl 2012;2:1–138.Google Scholar